Delivering reduced hands-on time, more consistent results and higher sample throughout

Oxford, UK, 24^th September.

OGT, a leading global provider of genomic research and diagnostic solutions today unveiled next-generation sequencing (NGS) automation capabilities across its SureSeq™ NGS portfolio, compatible with the Hamiton NGS STAR Line. The latest advancement in OGT’s ongoing SureSeq investment, these automated workflows help laboratories optimise resources and deliver turnaround time targets.

Amsbio announce a new partnership with Atelerix to introduce its patented hydrogel technology for the room-temperature storage and transportation of living cells, tissues, organoids and viruses.

New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact.

DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators.

Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa solutions, has moved into Colworth Science Park’s food tech incubator Gastronomica.

Gastronomica is a home for ambitious food-tech businesses advancing the future of food, enabling innovators and industry leaders to scale ideas, tackle global food shortages, and drive sustainable solutions.

Beacon for rare diseases, a Cambridge-based charity, has just launched Rare Insights – a ground-breaking study exploring the value and impact of rare disease patient groups, alongside the challenges they face.

Patient groups are often the first port-of-call for newly diagnosed patients with a rare disease. By providing much-needed support to individuals with rare diseases and their families, they become a lifeline, frequently advocating for research and helping to shape policies that put patients at their heart.

• Former Olink Proteomics President brings extensive life-science tools leadership experience, having helped lead Olink through its $3.1 billion acquisition by Thermo Fisher Scientific
• Co-founder and former CEO Dr Michael Chen transitions to Chief Scientific and Business Officer

Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets.

Established in 2005, Boyds provides specialist consultancy services to an international client base, supporting the development of new, cutting-edge medicines and medical devices for patient benefit.